Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Antitrust Risks of Co-Promotion and Co-Marketing Agreements in Pharmaceutical Patent Settlements Around the World

Speaking Engagement
In the wake of FTC v. Actavis and the European Commission's decisions against Lundbeck, J&J and Novartis, pharma patent settlement agreements remain an issue in the US and Europe. Among questions yet to be resolved is how co-promotion and co-marketing, and manufacturing arrangements that are part of patent settlement agreements should be analyzed by antitrust enforcers.

WilmerHale Partner Mark Ford will be a featured speaker on this panel.

Read More About the Event

Speakers